A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 - Related Studies

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

This study has been completed.

Study NCT00001383. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer
		Cancer
		Carcinoma, Renal Cell
		Lymphoma
		Ovarian Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Carcinoma
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Adnexal Diseases
		Breast Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Kidney Diseases
		Kidney Neoplasms
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Ovarian Diseases
		Skin Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		PSC 833
		paclitaxel

5	More general drug interventions related to this trial
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

6	Sponsors listed in this trial
		National Cancer Institute (NCI)